Comments
Loading...

Kymera Therapeutics

KYMRNASDAQ
Logo brought to you by Benzinga Data
$49.03
00.00%
Pre-Market: 4:07 PM EDT
15 minutes delayed
Consensus Rating1
Buy
Highest Price Target1
$65.00
Lowest Price Target1
$30.00
Consensus Price Target1
$46.47

Kymera Therapeutics (NASDAQ:KYMR) Stock, Analyst Ratings, Price Targets, Forecasts

Kymera Therapeutics Inc has a consensus price target of $46.47 based on the ratings of 19 analysts. The high is $65 issued by Wolfe Research on August 26, 2024. The low is $30 issued by B of A Securities on January 3, 2024. The 3 most-recent analyst ratings were released by Leerink Partners, Wolfe Research, and Morgan Stanley on September 9, 2024, August 26, 2024, and August 14, 2024, respectively. With an average price target of $56.67 between Leerink Partners, Wolfe Research, and Morgan Stanley, there's an implied 15.58% upside for Kymera Therapeutics Inc from these most-recent analyst ratings.

Analyst Trends and Forecast
0
0
0
0
Jun
1
1
Jul
1
2
Aug
1
Sep
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
3.2
Hold
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

Leerink Partners
Wolfe Research
Morgan Stanley
Wells Fargo
Oppenheimer

1calculated from analyst ratings

Analyst Ratings for Kymera Therapeutics

Data brought to you by Benzinga APIs

FAQ

Q

What is the target price for Kymera Therapeutics (KYMR) stock?

A

The latest price target for Kymera Therapeutics (NASDAQ:KYMR) was reported by Leerink Partners on September 9, 2024. The analyst firm set a price target for $60.00 expecting KYMR to rise to within 12 months (a possible 22.37% upside). 21 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Kymera Therapeutics (KYMR)?

A

The latest analyst rating for Kymera Therapeutics (NASDAQ:KYMR) was provided by Leerink Partners, and Kymera Therapeutics their outperform rating.

Q

When was the last upgrade for Kymera Therapeutics (KYMR)?

A

The last upgrade for Kymera Therapeutics Inc happened on August 26, 2024 when Wolfe Research raised their price target to $65. Wolfe Research previously had a peer perform for Kymera Therapeutics Inc.

Q

When was the last downgrade for Kymera Therapeutics (KYMR)?

A

The last downgrade for Kymera Therapeutics Inc happened on January 3, 2024 when B of A Securities changed their price target from $45 to $30 for Kymera Therapeutics Inc.

Q

When is the next analyst rating going to be posted or updated for Kymera Therapeutics (KYMR)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Kymera Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Kymera Therapeutics was filed on September 9, 2024 so you should expect the next rating to be made available sometime around September 9, 2025.

Q

Is the Analyst Rating Kymera Therapeutics (KYMR) correct?

A

While ratings are subjective and will change, the latest Kymera Therapeutics (KYMR) rating was a with a price target of $0.00 to $60.00. The current price Kymera Therapeutics (KYMR) is trading at is $49.03, which is within the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch